Suggestions
Zach Weinberg
Founder at Curie.Bio, Co-Founder of Flatiron Health and Experienced Angel Investor
Zach Weinberg is a successful entrepreneur and investor in the healthcare technology sector. He is currently the co-founder and CEO of Curie.Bio, a venture capital firm focused on helping founders launch therapeutics companies.13
Career Highlights
-
Curie.Bio: Co-founder and CEO since January 2022.2 Curie.Bio aims to support biotech founders in developing successful medicines and raising subsequent funding rounds.1
-
Flatiron Health: Co-founder, President and COO from June 2012 to March 2021. Flatiron Health was acquired by Roche in 2018 for $2 billion.24
-
Invite Media: Co-founder, President and COO. The company was acquired by Google in 2010 for approximately $100 million.12
-
Angel Investor: Active angel investor in multiple startups since June 2010.2
Entrepreneurial Approach
Weinberg has a track record of identifying opportunities in healthcare data and technology:
-
At Flatiron Health, he focused on extracting value from oncology electronic health records to improve clinical trial design and generate post-approval evidence.4
-
With Curie.Bio, he aims to enable more founder-led therapeutic companies by providing access to resources, expertise, and funding.4
Philosophy
Weinberg believes in empowering founders and increasing the number of "shots on goal" in biotech innovation. He sees an opportunity to make starting therapeutics companies more accessible and rewarding for individual entrepreneurs.4
Zach Weinberg's LinkedIn profile can be found at linkedin.com/in/zachweinberg.2
Highlights
Seems to me the real enemy here are the NY State laws/policies that allow crazy people with dozens of previous arrests to roam the streets and subways and threaten to kill people (and in some recent cases, actually kill people).
We cause inflation by handing out money, so in response to inflation, we hand out more money.
This is how socialist countries in South America have ruined their economies (among other dumb policies). When will we learn?
